Tumor News and Research

RSS

Epigenetics drug used to treat blood cancers, rare sarcomas can halt bladder cancer growth

An epigenetics drug currently being used for the treatment of blood cancers and rare sarcomas can stop the growth of bladder cancer by activating the immune system, reports a new Northwestern Medicine study done in mice.

5 Oct 2022

Researchers discover potential therapeutic target for deadly brain tumors

Researchers at VCU Massey Cancer Center discovered a cellular partnership that drives the growth of deadly brain tumors and could potentially serve as a novel target for disease treatment.

5 Oct 2022

Transient cell-in-cell formation by tumor cells found to build resistance to immunotherapy

Researchers demonstrated that tumor cells evade immunotherapy by generating unique transient cell-in-cell structures, resistant to chemotherapy and destruction by T cells.

5 Oct 2022

Novel protein vaccine NVX-CoV2373 triggered functional T cell responses to SARS-CoV-2

Researchers determined the T cell response to the NVX-CoV2373, an adjuvanted recombinant full-length SARS-CoV-2 spike (S) trimer protein vaccine.

5 Oct 2022

PSI researchers optimize a method for tumor diagnosis using radionuclides

Researchers at the Paul Scherrer Institute PSI, in collaboration with ETH Zurich, have optimized a method for tumor diagnosis using radionuclides.

5 Oct 2022

Small antiviral molecules termed assembly modulators show therapeutic efficacy against cancer

In a new study, researchers evaluated the anti-cancer therapeutic efficacy of two structurally-unrelated small molecules, PAV-617 and PAV-951.

4 Oct 2022

Stanford researchers discover a sustainable way to produce cancer-fighting compound in the lab

Stanford University researchers have discovered a rapid and sustainable way to synthetically produce a promising cancer-fighting compound right in the lab.

3 Oct 2022

Fungal involvement in tumors may drive worse cancer outcomes

The presence of some fungal species in tumors predicts - and may even help drive - worse cancer outcomes, according to a study from Weill Cornell Medicine and Duke University researchers.

3 Oct 2022

Collaboration aims to investigate ARTIDIS technology as novel treatment-optimization tool for solid tumors

The University of Texas MD Anderson Cancer Center and ARTIDIS AG today announced a strategic alliance to investigate ARTIDIS technology as a novel treatment-optimization tool for patients with solid tumors in several distinct indications.

3 Oct 2022

Researchers discover a molecule that promotes tumor cell survival in retinoblastoma

Despite decades of medical advances, children who develop the pediatric eye cancer retinoblastoma often lose their vision or an eye due to a lack of specific, targeted therapies and a poor molecular understanding of the cancer.

3 Oct 2022

Novel peanut-specific human IgE monoclonal antibodies may uncover new therapeutic targets for peanut allergy

A recent Frontiers in Immunology journal study by University of North Carolina at Chapel Hill and Vanderbilt University researchers has created an in vitro system to determine potential therapeutics targeting sensitized effector cells based on human, allergen-specific, Immunoglobulin E (IgE) monoclonal antibodies (mAbs).

2 Oct 2022

Study reveals immune characteristics of long-COVID

Researchers perform antibody profiling against SARS-CoV-2, several endemic pathogens, as well as vaccine antigens among rheumatic disease patients.

2 Oct 2022

Researchers discover how cancer cells can turn off the immune system to help tumors grow

When cancer arises in the body, it starts with tumor cells that rapidly grow and divide and eventually spread.

29 Sep 2022

Cancer cells 'hijack' a process used by healthy cells to spread around the body, research finds

Cancer Research UK-funded scientists have discovered that cancer cells 'hijack' a process used by healthy cells to spread around the body, completely changing current ways of thinking around cancer metastasis.

29 Sep 2022

CAR T-cell therapy produces impressive results in first clinical trial in patients with multiple myeloma

A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study published today by the New England Journal of Medicine.

29 Sep 2022

uPAR may be a promising target for therapy in patients with neuroendocrine neoplasms

A novel PET radiotracer can accurately assess the presence of a biomarker that indicates the level of tumor aggressiveness in neuroendocrine neoplasms (NENs).

28 Sep 2022

UAB study finds distinct kidney resident macrophage subpopulations located in spatially discrete microenvironments

Macrophages are immune cells that engulf and digest pathogens, cancer cells or cellular debris. The kidneys - like other tissues in the body - contain kidney resident macrophages, or KRMs, from the time of birth.

28 Sep 2022

Changes in temperature may be behind the link between circadian disruption and cancer

Disruptions in circadian rhythm - the ways that our bodies change in response to the 24-hour light and dark cycle - have been linked to many different diseases, including cancer.

28 Sep 2022

Houston Methodist researchers receive CPRIT funding to research two of the most lethal cancers

Two Houston Methodist cancer researchers have been awarded a half million dollars in funding from the Cancer Prevention and Research Institute of Texas to further research two of the most lethal, difficult-to-treat cancers that all-too-often have poor prognoses.

28 Sep 2022

Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma

A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72 percent survival rate) versus those who initially got targeted therapies (52 percent survival rate).

27 Sep 2022

Tumor News and Research

Epigenetics drug used to treat blood cancers, rare sarcomas can halt bladder cancer growth

Researchers discover potential therapeutic target for deadly brain tumors

Transient cell-in-cell formation by tumor cells found to build resistance to immunotherapy

Novel protein vaccine NVX-CoV2373 triggered functional T cell responses to SARS-CoV-2

PSI researchers optimize a method for tumor diagnosis using radionuclides

Small antiviral molecules termed assembly modulators show therapeutic efficacy against cancer

Stanford researchers discover a sustainable way to produce cancer-fighting compound in the lab

Fungal involvement in tumors may drive worse cancer outcomes

Collaboration aims to investigate ARTIDIS technology as novel treatment-optimization tool for solid tumors

Researchers discover a molecule that promotes tumor cell survival in retinoblastoma

Novel peanut-specific human IgE monoclonal antibodies may uncover new therapeutic targets for peanut allergy

Study reveals immune characteristics of long-COVID

Researchers discover how cancer cells can turn off the immune system to help tumors grow

Cancer cells 'hijack' a process used by healthy cells to spread around the body, research finds

CAR T-cell therapy produces impressive results in first clinical trial in patients with multiple myeloma

uPAR may be a promising target for therapy in patients with neuroendocrine neoplasms

UAB study finds distinct kidney resident macrophage subpopulations located in spatially discrete microenvironments

Changes in temperature may be behind the link between circadian disruption and cancer

Houston Methodist researchers receive CPRIT funding to research two of the most lethal cancers

Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News